JP2017530193A5 - - Google Patents

Download PDF

Info

Publication number
JP2017530193A5
JP2017530193A5 JP2017535616A JP2017535616A JP2017530193A5 JP 2017530193 A5 JP2017530193 A5 JP 2017530193A5 JP 2017535616 A JP2017535616 A JP 2017535616A JP 2017535616 A JP2017535616 A JP 2017535616A JP 2017530193 A5 JP2017530193 A5 JP 2017530193A5
Authority
JP
Japan
Prior art keywords
alkyl
heteroaryl
heterocycloalkyl
aryl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017535616A
Other languages
English (en)
Japanese (ja)
Other versions
JP6615207B2 (ja
JP2017530193A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/051143 external-priority patent/WO2016048861A2/en
Publication of JP2017530193A publication Critical patent/JP2017530193A/ja
Publication of JP2017530193A5 publication Critical patent/JP2017530193A5/ja
Application granted granted Critical
Publication of JP6615207B2 publication Critical patent/JP6615207B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017535616A 2014-09-22 2015-09-21 複素環式化合物及びその使用 Active JP6615207B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462053389P 2014-09-22 2014-09-22
US62/053,389 2014-09-22
PCT/US2015/051143 WO2016048861A2 (en) 2014-09-22 2015-09-21 Heterocyclic compounds and use thereof

Publications (3)

Publication Number Publication Date
JP2017530193A JP2017530193A (ja) 2017-10-12
JP2017530193A5 true JP2017530193A5 (enExample) 2018-11-01
JP6615207B2 JP6615207B2 (ja) 2019-12-04

Family

ID=55525127

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017535616A Active JP6615207B2 (ja) 2014-09-22 2015-09-21 複素環式化合物及びその使用

Country Status (12)

Country Link
US (2) US9862703B2 (enExample)
EP (1) EP3197885B1 (enExample)
JP (1) JP6615207B2 (enExample)
KR (1) KR102509431B1 (enExample)
CN (1) CN107207465B (enExample)
AU (1) AU2015321654B2 (enExample)
BR (1) BR112017005713B1 (enExample)
CA (1) CA2962329C (enExample)
ES (1) ES2849998T3 (enExample)
RU (1) RU2704008C2 (enExample)
TW (1) TWI598348B (enExample)
WO (1) WO2016048861A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018132326A1 (en) * 2017-01-10 2018-07-19 National Health Research Institutes Heterocyclic compounds and use thereof
PL3678668T3 (pl) * 2017-09-08 2024-06-03 The Board Of Trustees Of The Leland Stanford Junior University Inhibitory enpp1 i ich zastosowanie w leczeniu nowotworu
EP3842435A4 (en) 2018-09-20 2022-05-11 Hanmi Pharm. Co., Ltd. NEW SULFONAMIDE DERIVATIVE PRESENTING A FUSED PYRIMIDINE SKELETON, HAVING AN INHIBITOR EFFECT OF EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION
CA3128044A1 (en) * 2019-02-01 2020-08-06 The Board Of Trustees Of The Leland Stanford Junior University Enpp1 inhibitors and methods of modulating immune response
CN111138417B (zh) * 2019-12-18 2021-03-23 浙江工业大学 一种三氮唑修饰的5-氟-2,4-嘧啶二胺类化合物及其应用
TWI818651B (zh) * 2021-08-02 2023-10-11 財團法人國家衛生研究院 嘧啶化合物及其用途
IL320644A (en) * 2022-11-07 2025-07-01 Univ Kyoto Quinazoline derivatives
TW202435887A (zh) 2023-03-01 2024-09-16 瑞士商諾華公司 用於治療疾病或障礙的氫喹唑啉衍生物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4936700A (enExample) * 1972-08-16 1974-04-05
FI944602A0 (fi) * 1992-04-03 1994-10-03 Upjohn Co Farmaseuttisesti aktiiviset bisyklis-heterosykliset amiinit
US6156758A (en) * 1999-09-08 2000-12-05 Isis Pharmaceuticals, Inc. Antibacterial quinazoline compounds
CA2656290A1 (en) * 2006-07-05 2008-01-10 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
CN102015717A (zh) * 2008-03-28 2011-04-13 奥蒂瑞斯治疗公司 趋化因子受体调节剂
KR20110002465A (ko) * 2008-03-31 2011-01-07 젠야쿠코교가부시키가이샤 세포 보호 작용을 갖는 피리미딘 유도체 및 그 용도
HUE025179T2 (en) 2008-04-21 2016-02-29 Taigen Biotechnology Co Ltd Heterocyclic Compounds
WO2010046780A2 (en) 2008-10-22 2010-04-29 Institut Pasteur Korea Anti viral compounds
GB201015411D0 (en) 2010-09-15 2010-10-27 Univ Leuven Kath Anti-cancer activity of novel bicyclic heterocycles
MX342326B (es) 2011-09-27 2016-09-26 Novartis Ag 3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
EP2836240B1 (en) 2012-04-10 2019-03-13 Georgia State University Research Foundation, Inc. Compositions and methods for treating otitis media and other conditions with inhibitors of cyld
SI2906563T1 (en) 2012-10-10 2018-06-29 Janssen Sciences Ireland Uc Derivatives of pyrrolo (3,2-d) pyrimidine for the treatment of viral infections and other diseases
US20150259649A1 (en) * 2012-11-08 2015-09-17 Emory University Cellular compositions used to restore stem cell or progenitor cell function and methods related thereto

Similar Documents

Publication Publication Date Title
JP2017530193A5 (enExample)
RU2017109355A (ru) Гетероциклические соединения и их применение
PE20141700A1 (es) Compuestos de 2-(2,4,5-anilino sustituido) pirimidina
JP2014501766A5 (enExample)
CY1118909T1 (el) Αμιδια οξαλικου οξεος ως αναστολεις νεπριλυσινης, φαρμακευτικη συνθεση αυτων και παρασκευη αυτων
JP2016518328A5 (enExample)
JP2016516043A5 (enExample)
JP2016053042A5 (enExample)
AR086983A1 (es) Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak
JP2016515560A5 (enExample)
PE20190395A1 (es) Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos
PE20171177A1 (es) Compuestos aminopirimidinilo inhibidores de jak
JP2014506599A5 (enExample)
JP2016540803A5 (enExample)
JP2017509586A5 (enExample)
JP2007524696A5 (enExample)
RU2016135922A (ru) Терапевтические соединения и композиции
RU2013109132A (ru) Химические соединения
JP2015534574A5 (enExample)
AR081587A1 (es) DERIVADOS DE 5,6-DIHIDRO-2H-[1,4]OXAZIN-3-IL-AMINA UTILES COMO INHIBIDORES DE LA b-SECRETASA (BACE)
JP2020500869A5 (enExample)
JP2019529419A5 (enExample)
AR073551A1 (es) Pirimidinas macrociclicas como inhibidores de proteina cinasa
JP2017517512A5 (enExample)
AR046085A1 (es) Agonistas etilamino amino sustituidos del receptor beta 2 adrenergico